PDCD1 and cancer: Approximately two-third of patients were treated with PD-1 inhibitors, particularly pembrolizumab and nivolumab, whereas PD-L1 inhibitors and CTLA-4 inhibitors were administered in 19.1% and 4.8% of cancer patients.